Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.

Blood Adv · 2022 · PMC9631686 · PMID 35486475

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP < .001actually significant

Multivariate analysis of EFS showed a highly significant hazard reduction for an event for patients treated within the AMLSG 16-10 trial compared with the AMLSG historical control group (hazard ratio [HR], 0.55; P < .001); this effect was significant both in the younger (HR, 0.59; P < .001) and the older patient cohort (HR, 0.41; P < .001) ( Table 3 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.